1. Shahin Akhondzadeh, Seyed Hesameddin Abbasi. Herbal medicine in the treatment of Alzheimer's disease, American Journal of Alzheimer's Disease and Other Dementias, Volume 21, Number 2, March/April 2006, Page 113 – 118.
2. Katzman R: The Prevalence and Malignancy of Alzheimer's disease. A Major Killer. Arch Neurol. 1976; 33: 217-218.
3. Evans DA, Funkenstein HH, Albert MS: Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA. 1989; 262: 2551-2556.
4. Geldmacher DS, Whitehouse PJ: Differential diagnosis of Alzheimer's disease. Neurology. 1997; 48(Suppl 6): S2-S9. 4. World Health Organization: The ICD-JIO Classification ofMental and Behavioral Disorders. Geneva: World Health Organization, 1992.
5. Leopoldo Luiz dos Santos-Neto, Maria Alice de Vilhena Toledo, Patrı´cia Medeiros-Souza and Gustavo Almeida de Souza, “The Use of Herbal Medicine in Alzheimer’s Disease—A Systematic Review” Advance Access Publication 23 October 2006 eCAM 2006;3(4)441–445 doi:10.1093/ecam/nel071.
6. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Neurology 2001;56: 1154–66.
7. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease. An analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21:607–20.
8. Fran¸cois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of Memantine in moderately severe Alzheimer’s’ Disease. A Markov model in Finland. Clin Drug Invest 2004; 24:373–84.
9. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of donezepil in moderate to severe Alzheimer disease. Neurology 2004;63: 644–50.
10. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment. A randomized placebo-controlled trial. Neurology 2004; 63:651–7.
11. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 2004; 363:2105–15.
12. Mantle D, Pickering AT, Perry E. Medical Plant extracts for treatment of dementia. A review of their pharmacology, efficacy and tolerability. CNS Drugs 2000;13: 201–13.
13. World Health Organization: The ICD-JIO Classification ofMentaland Behavioral Disorders. Geneva: World Health Organization,1992.
14. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
15. McKhann G. Drachman D, Folstein M, et al.: Clinical diagnosis of AD: Report ofNINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on AD. Neuiology. 1984; 34: 939-944.2
16. Schneiders LS: An overview of rating scales used in dementia. Alzheimer Insights. 1996; 2: 1-7.
17. Selkoe DJ: Amyloid beta-protein and genetics of Alzheimer's disease. JBiol Chem. 1996; 27: 18295-18298.
18. Lue LF, Kuo YM, Roher AE: Soluble amyloid beta peptide concentration as a predictor of synaptic changes in Alzheimer's disease. AmJ Pathol. 1999; 155: 853-862.
19. Francis PT, Palmer AM, Snape M, et al.: The cholinergic, Veurozsurg Psj'chiatrjl 1999; 54: 137-147.
20. Wright CI, Geula C, Mesulam MM: Neurological cholinesterase in the normal brain and in Alzheimer's disease: Relation to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993; 34: 3 73-384.
21. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976; 2: 1457-1459.
22. Livingston G. Katona C: How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatric Psychiatry 2000; 15: 203-207.
23. Giacobini E: Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disord. 2000; 14: S3-S I 1.
24. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Safey. 1998; 19: 465-480.
25. Weinstock M: Selectivity of cholinesterase inhibition: Clinical implication for the treatment of Alzheimer's Dise'ase. CNS Drugs. 1999; 12: 307-303.
26. Bullock R: Drug treatment in dementia. Curr Opin Psychiatry 2001; 14: 349-353.
27. Bullock R: New drugs for Alzheimer's disease and other dementias. Br JPsychiatry. 2002; 180: 135-139.
28. Keltner NL, Beth Williams SN: Memantine: A new approach to Alzheimer's disease. Perspect Psychiatric Care. 2004; 40: 123-124.
29. Akhondzadeh S, Noroozian M: Alzheimer's disease: Pathophysiology and pharmacotherapy. IDrugs. 2002; 4: 1167-1172.
30. Bullock R: New drugs for Alzheimer's disease and other dementias. Br JPsychiatry. 2002; 180: 135-139.
31. Shadlen MF, Larson EB: What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Postgrad Med. 1999; 105: 109-118.
32. Mayeux R, Sano M: Treatment ofAlzheimer's disease. NEngl J Med. 1999; 34: 1670-1679.
33. Bush Al: Therapeutic targets in the biology ofAlzheimer's disease. Curr Opin Psychiatry. 2001; 14: 341-348.
34. Raskind MA, Peskind ER, Wessel T: Galantamine in AD: A six month randomized placebo-controlled trial with a six month extension. Neurology. 2000; 54: 2261-2268.
35. Kanowski S, Hoerr R: Proof of the efficacy of the Ginkgo biloba special extract egb76 1 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type of multi-infarct dementia. Phytomedicine. 1997; 4: 215-222.
36. Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997; 278: 1327-1332.
37. De Feudis FV: Ginkgo biloba Extract EGb761. Pharmacological Activities and Clinical Applications. Paris: Elsevier, 1991.
38. Kleijnen J: Ginkgo biloba. Lancet 1992; 340: 1136-1139.
39. Wettstein A: Cholinesterase inhibitors and ginkgo extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine. 2000; 6: 393-40 1.
40. Dore S, Bastianetto S, Kar S, et al: Protective and rescuing abilities of IGF-I and some putative free radical scavengers against betaamyloid- inducing toxicity in neurons. Ann N YAcad Sci. 1999; 890: 356-364.
41. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003; 36: 297-303.
42. Schulz V: Ginkgo extract or cholinesterase inhibitors in patients with dementia: What clinical trials and guidelines fail to consider. Phytomedicine. 2003; 10(Suppl) 14: 74-79.
43. Kurz A, Van Baelen B: Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: A review based on meta-analyses by the Cochrane collaboration. Dementia Geriatr Cogn Disord. 2004; 18: 217-226.
44. Xu SS, Gao ZX, Weng Z: Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li XueBao. 1995; 16: 391-395.
45. Zhang RW, Tang XC, Han YY: Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao LiXue Bao. 1991; 12: 250-252.
46. Zhang Z, Wang X, Chen Q: Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease: A placebo-controlled, double-blind, randomized trial. Zhonghua Yi XueZaZhi. 2002; 82: 941-944.
47. Xu SS, Cai ZY, Qu ZW: Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao. 1999; 20: 486-490.
48. Szatmari SZ, Whitehouse PJ: Vinpocetine for cognitive impairment and dementia; Cochrane Database Syst Rev. 2003; CD003 119.
49. Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6: 31-43.
50. Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. JAm Geriatr Soc. 1987; 35: 425 -430.
51. Fenzl E, Apecechea M, Schaltenbrand R: Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. In Krieglstein J (ed): Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. New York: Elsevier Science Publishers; 1986: 430-434.
52. Manconi E, Binaghi F, Pitzus F: A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr Ther Res Clin Exp. 1986; 30: 702-709.
53. Peruzza M, DeJacobis M: A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther. 1986; 3: 201-209.
54. Blaha L, Erzigkeit H, Adamczyk A: Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum Psychopharmacol. 1989; 4: 103-1 1 1.
55. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. JAltern Complement Med 1998; 4: 419-428.
56. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: From etnobotany to phytotherapy. J Pharm Pharmacol. 1999; 51: 527-534.
57. Kennedy DO, ScholeyAB, Tildesley NTJ, et al.: Modulation ofmood and cognitive performance following acute administration of Melissa officinalis lemon balm. Pharmacol Biochem Behav. 2002; 72: 953-964.
58. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. JNeurol Neurosurg Psychiatry. 2003; 74: 863-866.
59. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003; 28: 53-59.
60. Wake G, Court J, Pikering A, et al.: CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. JEthnopharmacol. 2000; 69: 105-114.
61. Schulz V, Hansel R, Tyler VE: Rational Phytotherapy. A Physicians 'Guide to Herbal Medicine, 3rd ed. Berlin: Springer- Verlag, 1998.
62. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
63. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.
64. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996;156: 661–6.
65. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003;28:53–9.
66. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebocontrolled trial. J Neurol Neurosurg Psychiatr 2003;74:863–6.
67. Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N e cols. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatr 2005;66:248–52.
68. Iwasaki K, Kobayashi S, Chimura Y, Taguchi M, Inoue K, Cho S e cols. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine ‘Ba Wei Huang Wan’ in the treatment of dementia. J Am Geriatr Soc 1994;52:1518–21.
69. Birks J, Grimley EJ. Ginkgo biloba for cognitive impairment and dementia. The Cochrane Library, Issue 2, 2004. Oxford: Update Software.